Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease
GSK announced results of the PD Phase III study by Impax Pharma, of IPX066 versus IR CD-LD patients experiencing motor fluctuations.
-
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint
GSK and Tolerx announced Phase III DEFEND-1 study of otelixizumab did not meet the PFS at month 12 in patients with type 1 diabetes.
-
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus
GSK & HGS announced that the FDA has approved Benlysta for the treatment of active, autoantibody-positive SLE who are receiving therapy.
-
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board (1)
GSK announces, Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board from 1/4/11.
-
Regulatory update: Nimenrix® (MenACWY vaccine)
GSK submitted a MAA to EMA for Nimenrix, active immunisation against meningococcal diseases caused by Neisseria meningitidis serogroups.
-
GSK outlines new plan to drive recruitment and attract graduate talent in the UK
GSK outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company.
-
Reward for charities bridging gaps in health care provision
Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care, part of GSK IMPACT Awards.
-
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare today announced a breakthrough in dental care with the launch of new Sensodyne Repair & Protect.
-
David Redfern appointed as new Chairman of ViiV Healthcare
GSK, ViiV & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1/4/11.
-
GSK European regulatory update on Pandemrix™ (1)
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
-
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GSK announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme.
-
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GSK & LRY announced they signed a 15.5-year lease for a new building to be developed by Liberty Property Trust and Synterra Partners.
-
GSK revises US Avandia label to include new restrictions on use
GSK announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines.
-
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GSK & HGS announced publication Benlysta in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.
-
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth, increasing pipeline potential and improved cash generation.
-
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK & THRX announced major milestones in two clinical development programmes focused on new treatments for patients with COPD.
-
GSK announces the sale of its entire shareholding in Quest Diagnostics
GSK announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (Quest).
-
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases in Finland.
-
GSK and Actelion discontinue clinical development of almorexant
GSK & ATLN announced the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued.
-
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GSK received a Complete Response letter from the FDA for the sNDA for Avodart for reducing the risk of prostate cancer in men.